Presentation at Japan Innovation Campus on Diabetes Cure and Biozipcode Technology

Silicon Valley, USA — We were honored to present at the Japan Innovation Campus, an initiative hosted by the Ministry of Economy, Trade and Industry (METI), operated by Mori Building Co., Ltd. and Mori Building Palo Alto, Inc., and partnered with JETRO. The event serves as a bridge between Japan’s most promising ventures and leading global investors, providing an environment where innovative companies can engage directly with venture capital firms, corporate leaders, and policymakers. Our participation offered the opportunity to showcase groundbreaking medical research and to exchange views with an international audience of decision-makers.

During the session, our team delivered a pitch presentation and an open discussion focused on the urgent global challenge of diabetes and the potential of scientific innovation to provide a definitive cure. We highlighted the limitations of conventional treatments, which primarily manage blood glucose levels without addressing the underlying causes. In contrast, our approach targets the root of the disease: abnormal hematopoietic stem cells. By combining HDAC inhibitors with insulin and leveraging advanced biomarkers, we aim to achieve complete remission, moving beyond management to cure.

A central feature of the presentation was our proprietary Biozipcode™ drug delivery technology. Inspired by Japan’s postal code system, Biozipcode™ uses a unique seven-amino-acid sequence to deliver therapeutic agents only to specific target cells. This innovation not only maximizes therapeutic efficacy but also minimizes side effects, enabling safer and more effective treatments. By integrating Biozipcode™ with our diabetes cure protocol, we aim to establish a global model of precision medicine, with implications not only for diabetes but also for cancer, autoimmune diseases, and regenerative therapies.

The discussions with investors and venture capitalists underscored the significance of combining medical innovation with sustainable business models. Participants expressed strong interest in the societal and economic impact of a curative therapy for diabetes, a disease that affects more than 500 million people worldwide and imposes over USD 1 trillion in annual costs. We are deeply grateful to the organizers of the Japan Innovation Campus for providing this platform and to the many stakeholders who engaged with us during the event. Together, we look forward to advancing both the science and the ecosystem that will make curative therapies accessible worldwide.